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Introduction.TheMANGUA cohort is an ongoing multicenter, observational study of people living with HIV/AIDS in Guatemala.
The cohort is based on theMANGUA application which is an electronic database to capture essential data from themedical records
of HIV patients in care. Methods. The cohort enrolls HIV-positive adults ≥16 years of age. A predefined set of sociodemographic,
behavioral, clinical, and laboratory data are registered at entry to the cohort study. Results. As of October 1st, 2012, 21 697 patients
had been included in the MANGUA cohort (median age: 33 years, 40.3% female). At enrollment 74.1% had signs of advanced HIV
infection and only 56.3%had baseline CD4 cell counts. In the first 12months after starting antiretroviral treatment 26.9% (𝑛 = 3938)
of the patients were lost to the program. Conclusions.The implementation of a cohort of HIV-positive patients in care in Guatemala
is feasible and has provided national HIV indicators to monitor and evaluate the HIV epidemic. The identified percentages of late
presenters and high rates of LTFU will help the Ministry to target their current efforts in improving access to diagnosis and care.
1. Introduction
Currently, in Guatemala the HIV epidemic is concentrated
in most-at-risk populations, with prevalence between 4 and
15% among commercial sex workers and 11.5–18.3% among
men who have sex with men. HIV prevalence among other
vulnerable groups is 18% in people with tuberculosis (TB),
13% in prison populations, and 3.3% among youth at social
risk [1–3]. During the period 2001–2005, with the support
fromMédecins Sans Frontières, four hospitals were providing
antiretroviral treatment (ART) in Guatemala. In 2004, in
alignment with the World Health Organization (WHO) 3-5
strategy and with financial aid from the Global Fund to
fight AIDS, tuberculosis, and Malaria (the Global Fund),
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Table 1: Standardized variables collected in MANGUA.
Sociodemographic and
behavioral variables
MANGUA study code, date of enrollment, gender, date of birth, country of origin, province of residence,
ethnicity, religion, marital status, educational level, employment status, name of UAI, previous treatment,
casualty date, casualty cause, cause of death, informed consent signed, vulnerability group, transmission
group, probable year of infection, sexual orientation, and condom use.
Laboratory variables
Biochemistry and hematology variables, HIV rapid test, HIV ELISA test, serologies for toxoplasma,
cytomegalovirus, histoplasma, cryptococcus, HBV, HCV, HSV, and syphilis. Sputum-smear microscopy
for tuberculosis.
Clinical variables WHO clinical stage, date of visit, type of visit, date of next scheduled visit, CD4 count, CD8 count, HIVRNA viral load, AIDS-related events, AIDS-defining events, and other coinfections.
Treatment variables ART type, prophylaxis type, other treatments, initiation and stop date
∗, reason for regime change∗, and
adverse effects∗.
HBV: human hepatitis B virus; HCV: human hepatitis C virus; HSV: human herpes virus simplex types I and II. UAI: Unidad de atención integral; ELISA:
enzyme-linked immunosorbent assay; RNA: ribonucleic acid; and ART: antiretroviral treatment.
∗For each type of treatment.
the Ministerio de Salud Pública y Asistencia Social (MSPAS)
started to implement specialized hospital-based HIV units—
Unidades de Atención Integral (UAIs)—across the country;
therefore, extending ART coverage and increasing access to
care for people living with HIV/AIDS (PLHIV) [4–6]. UAIs
are administered by minimal essential staff: a physician, a
nurse, a laboratory technician, and a social worker. Currently
16 UAI offer combination antiretroviral therapy (cART) free
of charge (Figure 1).
In a collaborative effort between the National AIDS
Program (PNS) of the MSPAS and the Fundació Sida i
Societat (FSiS), a Catalan non-governmental organization
working in global health, the HIV electronic medical record
(EMR) application, MANGUA, was developed in 2006 to be
implemented in all theUAIs ofGuatemala.Thepurpose of the
MANGUA application was to facilitate clinical management
and provide data for national HIV indicators to the MSPAS.
The MANGUA application is registered in Catalonia, Spain,
and was designed and piloted with the support of the HIV
department at the Cĺınica Familiar Luis Ángel Garćıa in
Guatemala City.The use of theMANGUA application rapidly
expanded along with the roll-out and scale-up of UAIs.
MANGUA is a database application structured in query
language (SQL server 2008 R2, Microsoft, Redmond, WA
98052). It was developed as an EMR to capture demographic,
behavioral, clinical, and laboratory information for HIV-
positive individuals enrolled in health care services in the
UAIs [1, 7].
The MANGUA cohort is an ongoing multicenter,
prospective observational study based on the data captured
in theMANGUA application; its main objective is to generate
outputs to improve both public health and clinical practice
related to HIV/AIDS in Guatemala.
2. Methods
Currently, 14 of the 16 current UAIs participate in the cohort.
21 697 HIV-positive adults ≥16 years of age are enrolled.
Data are collected by the medical staff of the UAIs following
the national ethical guidelines. The cohort includes 74.3%
of the cumulative number of HIV-positive patients reported
to the national health authorities in 2012 (𝑛 = 29 211) [5].
Patients are eligible to enter theMANGUAcohort when there
is confirmation of a positive HIV rapid test either with an
enzyme-linked immunosorbent assay (ELISA) or a second
highly specific rapid test. Discordant results are confirmed
by Western blot. Patient informed consent is obtained before
performing anyHIV test. Participants are recruited at theUAI
at HIV diagnosis, referred from primary and secondary level
health care centers, or voluntary counseling and testing sites.
HIV testing is repeated at the UAI for confirmation. Local
policy regarding informed consent for HIV testing is applied.
Data were retrospectively collected from 2001 to 2006,
and then, prospectively collected from 2006 onwards. In each
UAI there is at least one data entry manager who registers
routine health care data obtained from papermedical records
into the MANGUA application. Retrospective clinical data
dates back to the time of the patient’s initial HIV diagnosis
or when the clinician first visited the patient. The database is
regularly updated to contain follow-up status.
Data are anonymized and sent periodically to Unidad
de Apoyo Técnico (UAT) at the FSiS, and to the National
Health Care Database (SIGSA), where data are checked for
quality before returning to the UAI. All data are stripped
of names and other personal identification and a unique
MANGUA study code is assigned to each participant to
protect confidentiality.
Every two months an interdisciplinary quality control
team composed of UAT staff and data managers from PNS
visits each UAI to perform source-to-database data audits.
At these visits the quality control team selects at random a
proportional sample of participants’ medical records, such
as clinical and laboratory reports, and MANGUA data are
reviewed against this original documentation [8].
To guarantee the continual improvement of data validity,
UAT data managers generate lists of potential errors (i.e.,
initiation of ART before HIV diagnosis, etc.) and check for
inconsistencies and missing data [1, 9]. A MANGUA data
dictionary and user manual was developed and distributed
among UAI personnel. Descriptive analyses are approved by
the PNS and MSPAS. A predefined set of sociodemographic,
behavioral, clinical, and laboratory data are recorded at first
entry to the cohort study and subsequent visits (Table 1).
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Number of patients by department
5001–12500
1001–5000
501–1000
0–500 
Departments without UAI
Number of UAIs and number of patients attended at each UAI by Guatemalan department
(1) Guatemala, 4 UAIs: Clínica Familiar Luis Ángel García, San Juan de Dios Hospital (n = 3887). Infectious Diseases 
Clinic, Roosevelt Hospital (n = 7270). Hospital del Instituto Guatemalteco de Seguridad Social 
(IGSS) (n = 1273). Sanidad Militar (n ≈ 60. UAI not participating in MANGUA cohort. Data not included)
(2) Huehuetenango, 1 UAI: Hospital Departamental de Huehuetenango Dr. Jorge Vides Molina (n = 75)
(3) Sacatepéquez, 2 UAIs: Hospital Nacional Pedro Bethancourt, Antigua (n = 285). Hospicio de San José (n = 363)
(4) Zacapa, 1 UAI: Hospital Nacional Carlos Arana Osorio (n = 415)
(5) Izabal, 2 UAIs: Hospital Nacional de la Amistad Japón-Guatemala de Puerto Barrios (n = 1891). Hospital Infan-
til Elisa Martinez (n ≈ 60. UAI not participating in MANGUA cohort. Data not included)
(6) Quetzaltenango, 3 UAIs: Juan José Ortega de Coatepeque National Hospital, Coatepeque (n = 3252). Hospital 
Regional de Occidente San Juan de Dios (n = 226). Clínica Isaac Cohen Alcache, Hospital Nacional
(7) Escuintla, 1 UAI: Hospital Nacional Regional de Escuintla (n = 816)
(8) Petén, 1 UAI: Hospital Nacional de San Benito Petén (n = 523)
(9) Santa Rosa, 1 UAI: Hospital Nacional de Cuilapa (n = 247)
UAI: Unidad de atención integral
Rodolfo Robles (n = 1174)
Figure 1: Number of UAIs and number of patients attended at each UAI by Guatemalan department.
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Table 2: Patient characteristics at enrollment in the MANGUA cohort.
(𝑛, % of available data from variable) Total Men Women 𝑃 value∗
𝑛 % 𝑛 % 𝑛 %
Gender (𝑛 = 21 697, 100%)
Age in years (𝑛 = 21 629, 99.7%)
<0.0001
Median, IQR 33 (27–42)
16–24 3660 16.8 1616 44.5 2013 55.5
25–49 15079 69.1 9182 61.4 5779 38.6
≥50 3073 14.1 2106 68.6 964 18.6
Ethnic group (𝑛 = 12 172, 56.1%)
Ladino 9842 80.9 5881 59.8 3961 40.2 0.91
Indigenous 2330 19.1 1395 59.9 935 40.1
Transmission route (𝑛 = 12 592, 58%)
<0.0001
Heterosexual 11709 92.5 6593 56.4 5102 43.6
Homosexual 907 7.2 844 98.1 16 1.9
Injection drug users 40 0.3 34 91.9 3 8.1
Advanced HIV at enrollment∗∗ (𝑛 =
10892, 50.2%) 4168 38.3 2778 66.7 1390 33.3 <0.0001
CD4 cells/mL at enrollment (𝑛 = 12219,
56.3%)
<0.0001
Median, IQR 131 (46–279)
≥350 2129 17.4 956 44.9 1173 55.1
200–349 2311 18.9 1203 52.1 1108 47.9
<200 7779 63.7 5208 66.9 2571 33.1
cART status at enrollment (𝑛 = 8919,
41.1%)
Naive 7981 89.5 4793 60.1 3188 39.9 0.01
Previous treatment 938 10.5 550 58.6 388 41.4
Median (IQR) time in days between HIV
diagnosis and cART initiation in days
(𝑛 = 13195, 60.8%)
75 (27–308) NA∗∗∗ 70 (28–247) NA 86 (26–388) NA 0.97
∗
𝑃 values were calculated taking into account that transexuals (𝑛 = 152) were added to men for statistical convenience.
𝑃 < 0.05 was considered as statistically significant.
∗∗Clinical stages 3 and 4 fromWHO.
∗∗∗Not applied.
IQR: interquartile range; cART: combination antiretroviral therapy.
Classification of AIDS-defining events is based on WHO
criteria [10]. At each quarterly or semiannual follow-up visit,
laboratory and clinical data are obtained and updated into the
MANGUA database.
2.1. Statistical Analysis. Data were analyzed using STATA
software version 11, (StataCorp LP, College Station, TX,USA).
Sociodemographic and clinical characteristics at enrollment
were compared using Pearson 𝜒2 test for categorical variables
and Student’s 𝑡-test for continuous variables.
3. Results
As of October 1st, 2012, 21 697 patients had been included in
the MANGUA cohort (median age: 33 years, 40.5% female).
The cohort has 45 853 person-years of follow-up, with
a median follow-up time of 1.1 years. Percentages of patients
with available data on the following variables are as follows:
transmission route (58%), cART status at enrollment (41.1%),
advanced HIV status at enrollment (50.2%), and CD4 cell
counts at enrollment (56.3%). Among these patients with
available data most, 92.9% (11 709/12 592), were infected by
heterosexual relations. At enrollment, 89.3% (8169/9144)were
naive and 74.1% (12 075/16 300) had signs of advanced HIV
infection (CD4 cell counts < 350 cells/mm3 or WHO clinical
stage 3 or 4) [10]. Only 56.3% (12 219/21 697) had baseline
CD4 cell counts, of whom 63.7% (7782/12 222) had CD4 cell
counts <200 cells/mm3 (Table 2).
During follow-up, 67.4% (14 616/21 697) started ART of
which 98% started cART.At cART initiation, themedianCD4
cell count was 126 cell/mm3 (Interquartile range [IQR]: 47–
240). The treated cohort has 41 741 person-years of follow-up
and a median follow-up time of 2.3 years.
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Retention analysis was based on the definition described
elsewhere [11, 12]. Retention proportions of living HIV-
positive adults on active cART were calculated at 12 and 24
months after cART initiation. Pre- and postdecentralization
periods should be differentiated. During the 2001–2005
predecentralization period the average retentionwas 84%and
79.7% at 12 and 24 months, respectively, with 2095 patients
starting cART. For the 2006–2011 postdecentralization
period, the average retention was 65.3% and 55.5% at 12 and
24 months, respectively, with 11 265 patients starting cART.
Overall, for the 11-year period 2001–2011, the average
retention proportion was 73.8% and 61.5% at 12 and 24
months, respectively.
Attrition analysis was adapted from definitions described
elsewhere [11, 13] and was defined as episodes of discontinua-
tion of cART at the end of a follow-up period for the following
reasons: death, loss to follow-up (LTFU), or stopping ART
for any other reason while remaining in care. LTFU included
the following two situations [14]. The first situation applies
when patients are permanently LTFU for a 12-month period
during which any additional patient visits disqualified them
as permanently LTFU. In this situation, a differentiation was
made between patients with no follow-up, defined as those
that did not return to the clinic after the first visit scheduled
for cART initiation, and patients with LTFU after starting
cART, defined as those who start cART and are lost to follow-
up for at least 180 days after the last visit scheduled. The
second situation applies to patients LTFUwho later reentered
follow-up, defined as those who start cART and return for at
least one visit after which the patient is not seen in the clinic
for ≥180 days after the last visit scheduled but reappears at the
clinic from at least day 181 onwards.
In order to calculate the global LTFU rate, the analysis
took into account that a single patient might have had more
than one episode of LTFU. Thus, during 41 741 person-years
of follow up, 8572 episodes of LTFU (including cART stops
for other reasons), were recorded with a rate of 20.5 per 100
person-years, very close to the rates seen elsewhere [14].
Attrition rates at 6- and 12-month follow-up period were
studied; the 6-month interval was chosen to be consistent
with the LTFU definition used; the 12-month interval was
used to analyze the evolution of LTFU episodes and to be able
to compare LTFU outcomes with retention rates. In the first 6
months after starting cART, 19% (𝑛 = 2785) of patients were
lost to the program: 575 patients (20.6%) did not return to
the clinic after cART initiation (no follow-up), 1568 (56.3%)
were LTFU (including cART stops for other reasons), and 642
(23.1%) died. In the first 12 months after starting cART 26.9%
(𝑛 = 3938) of patients were lost to the program: 618 patients
(15.7%) did not return to the clinic after cART initiation (no
follow-up), 2510 (63.7%) were LTFU (including cART stops
for other reasons), and 810 (20.6%) died.
Future measurements will include an analysis of LTFU
risk factors, late diagnosis, and incidence of opportunistic
infections by CD4 cell counts. It is also necessary to measure
death outcomes in patients starting cART and the incidence
of side effects of cART.
4. Discussion
This is the largest cohort of HIV-positive people compiled in
Central America and the cohort has a wide representation of
the total HIV population registered throughout Guatemala.
The MANGUA cohort has a nationwide, population-based
design, with long-term follow-up. National scale-up of cART
has resulted in a considerable number of patients enrolled in
HIV treatment and care for HIV prevention and control in a
country constrained by limited resources.
The MANGUA application was implemented soon after
the scale-up of UAIs; in 2004 only 4 UAIs existed in the
country; in 2008, 12 UAIs were already functioning. Scale-up
of UAIs was possible because of international financial aid,
mainly from the Global Fund, and the commitment of the
MSPAS to decentralize HIV care in Guatemala.This scenario
facilitated the acceptability of an EMR by UAI professionals,
because it allowed systematization and harmonization of data
collection and analysis. Comprehensive training activities
were targeted to professionals, physicians, nurses, and data
entry personnel, on how to use the MANGUA application.
The implementation of the MANGUA cohort has been
successful and has proven to be useful for both clinicians and
the PNS through the provision of data for key HIV indicators
to monitor the HIV epidemic in Guatemala. The MANGUA
application has been integrated within the SIGSA web infor-
mation system, which is crucial to ensure sustainability and
strengthen HIV monitoring and surveillance in Guatemala.
Nevertheless, only approximately half of the patients
registered in the cohort have data available onCD4 cell counts
at baseline, partly due to under-notification and the fact that
only some UAIs have available CD4 cell count analyzers.
Among those with baseline data on CD4 cell counts, as much
as 82.6% do not present forHIV testing until advanced symp-
toms of HIV infection (CD4 cell counts < 350/mm3). Late
presenters are oftenmore ill, have a highermortality risk, and
are less likely to respond to treatment after initiation [15–18].
According to the Guatemalan National Guidelines on
HIV Diagnosis and Treatment, adults with WHO clinical
stage disease 3 or 4 or CD4 cell counts < 350 cells/mm3
are eligible for cART [19]. However, 65.1% of those eligible
patients do not start cART treatment and many of them are
LTFU (Figure 2).
Delayed cART initiation has been reported to be the
major cause of death and associated morbidity in HIV/AIDS
patients [20, 21]. This fact, together with late presentation
for HIV diagnosis and care and high LTFU, remains a
significant challenge to efficiently prevent morbidity and
mortality outcomes. It is worrisome that 30.1% (2582/8572) of
patients considered LTFU return to the hospital after having
interrupted ART for at least 6 months, which increases their
risk of developing drug resistance or death [22–24]. Efforts
should be focused on identifying reasons for LTFU with
strategies to minimize it, such as creating interdisciplinary
teams to investigate its underlying causes, proposing solu-
tions that have shown to be effective in other contexts [25, 26],
and expanding treatment access points in order to reduce
time spent travelling to the clinic.
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HIV patients enrolled
in MANGUA
Patients starting 
cART
7981
5725 (71.7%)
5725 (100%)
3725 (65.1%)
3326 (89.3%)
21697
16300 (75%)
12075 (74.1%)
8102 (67.1%)
TotalNaive(𝛼)
HIV patients with data 
on eligibility for cART 
initiation(𝛽)
Patients eligible for 
cART initiation(𝜒)
2NRTI(𝛿) + NNRTI(𝜀)
(𝛼)We excluded 975 patients that were retreated or reenrolled since we lack data on treatment regimen
Patients with data on baseline CD4 cell count or on AIDS-related events available(𝛽)
initiation over HIV patients with data on eligibility for cART initiation with data on treatment eligibility
(𝛿)Nucleoside reverse transcriptase inhibitor
(𝜀)Nonnucleoside reverse transcriptase inhibitor
(𝜒)CD4 cell count <350 cell/mm3 or WHO clinical stage 3 or 4. Number of patients eligible for cART
Figure 2: Spectrum of cART initiation in patients enrolled in MANGUA cohort.
Retention analysis reveals that the postdecentralization
period has less retention proportions than the predecentral-
ization period. This might be explained by different factors;
first, the number of HIV-positive patients starting cART in
the postdecentralization period is 5.4 times higher than in
the predecentralization period; and second, recently created
UAIs might have less capacity to provide integrated care to
HIV-positive patients, lacking the experience to effectively
implement adherence and follow-up interventions.
5. Conclusions
Today, the MANGUA HIV cohort is a powerful tool for
monitoring and evaluation as well as for research on HIV-
positive patients in respect to (i) epidemiologic patterns of
the HIV epidemic, (ii) delayed access to cART and burden of
opportunistic infections, (iii) risk factors for LTFU and late
diagnosis, and (iv) long term cART outcomes.
The strengths of this cohort include its size and the
representativeness of data collected from almost all registered
HIV patients in Guatemala gathered from 14 of the 16
UAIs. As a main strength, data within MANGUA covers
the spectrum of engagement in care, including late HIV
diagnosis, suboptimal linkage to and retention in HIV care,
insufficient use of antiretroviral therapy, and suboptimal
adherence to therapy [27].
In Guatemala, the AIDS surveillance system is composed
of several sources of information that are not yet linked.
As a result, the system is highly heterogenic and complex,
making it difficult to extract data for decision making [28].
Information on quality of the AIDS surveillance system is
lacking, that is, whether it is representative of the whole
country and updated in a timely manner and its level of
completeness and accuracy. The MANGUA database is con-
tributing to the harmonization of HIV national surveillance
data. In 2012, it gained recognition from national stakehold-
ers and UNAIDS Guatemala as the official HIV application
system. Some limitations should be noted. The MANGUA
cohort has not yet reached 100% of registered HIV-positive
patients declared to the MSPAS (29 211). Moreover, neither
the MSPAS nor MANGUA has the ability to register HIV-
positive patients from private health care centers throughout
Guatemala; thus, selection bias in the MANGUA cohort
might be a limitation.
The cohort is dependent on the quality of data entered by
data entry managers fromwritten medical records; therefore,
long standing and skilled staff are required to maintain the
quality of the clinical data, which is not always feasible.
We attempt to validate clinical data and provide feedback
to the UAIs in order to minimize errors and improve data
recording. Nonetheless, data omissions, duplicated patient
records, and incomplete and out-of-date laboratory and
sociodemographic information might occur. In fact, there is
a high proportion of missing data in key variables such as
CD4 cell counts at baseline, treatment status at enrollment,
transmission route of infection, and clinical stage category.
This limits the ability to draw conclusions from the entire
cohort because of data representativeness and selection bias
due to differences in characteristics of patients with data
available compared to patients without complete data avail-
able. In most UAIs it is not possible to maintain comput-
erized records; clinical data are collected for administrative
purposes rather than for clinical ones. Although the MSPAS
is currently working through this, there is no standardized
paper-based instrument shared in all UAIs to collect the
essential variables recorded in MANGUA cohort, which
would help in homogenizing data collection.
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The MANGUA cohort is not linked with the national
registry of deaths; consequently, there is little information on
AIDS-related deaths, and mortality rates may be underesti-
mated. In addition, TB and HIV services are not well inte-
grated in Guatemala. TB screening of HIV-positive patients
is poorly performed in UAIs and patients are referred to the
primary health care center for TB preventive chemotherapy
and treatment. Thus, data entry managers from UAIs lack
information on TB treatment outcomes on HIV patients,
hampering data entry into the MANGUA application from
the UAIs, and underestimating TB associated incidence
among HIV-positive people.
Nevertheless, the two main limitations are: first, the
MANGUA application is not used directly by medical staff
as an EMR inmost UAIs, rather data are collected initially on
paper and then digitalized. The process of informatization of
the UAIs in the country may, on a medium-term basis, con-
tribute to correct this situation. Second, high rates of LTFU
may introduce selection bias due to differences in follow-up.
UAI decentralization needs to be consolidated to partly over-
come this problem, the stabilization of the staff in peripheral
UAIs being one of its main challenges, which will assure the
continuum of care and facilitate adherence to treatment.
The MANGUA cohort aims to put Guatemalan HIV/
AIDS research on a par with other international collab-
orations in the field. This will be achieved through the
development of a nationally and internationally recognized
policy-relevant program of research in HIV therapy and
public health and through the establishment of training and
research opportunities to graduate students, postdoctoral
fellowships, and clinicians across the country.
Our efforts to improve research dissemination to physi-
cians and PLHIV as well as to improve knowledge and trans-
lational research will contribute to global recognition of the
MANGUA cohort. Over the past 6 years, we have expanded
our capacity to recruit participants, collect, extract, and
analyze data, and engage clinicians, policy stakeholders, and
funders. We are committed to share and promote MANGUA
research findings to help shape programs and policy that will
improve the lives of PLHIV in Guatemala and elsewhere.
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Guatemala; José Fernando Ortiz and Edwin Leslie Cam-
branes Morales, from Hospital del Instituto Guatemalteco de
Seguridad Social (IGSS), Guatemala City, Guatemala; Vilma
Reyes, from Hospital Departamental de Huehuetenango
Dr. Jorge Vides Molina, Huehuetenango, Guatemala; Car-
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